PIK3CA and breast carcinoma: In some cases, despite an international therapeutic consensus with significant evidence levels, the immune checkpoint inhibitor has not yet been approved in Japan, and there are no clinical trials on the immune checkpoint inhibitors, such as those related to PIK3CA alterations in breast cancer.